Tech Company Financing Transactions
ALZpath Funding Round
On 7/18/2023, ALZpath secured funding from private investors.
Transaction Overview
Company Name
Announced On
7/18/2023
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer's disease. This investment will enable ALZpath to continue generating clinical evidence and to launch an LDT version of the assay as ALZpathDx. The ALZpath pTau217 assay is currently available for research use only (RUO) through Quanterix, as a kit and for services in the Quanterix Accelerator laboratory.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
2292 Faraday Ave
Carlsbad, CA 92008
USA
Carlsbad, CA 92008
USA
Phone
Website
Email Address
Overview
ALZpath provides diagnostic tools and expertise in Alzheimer's disease. We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Venkat Shastri
Chief Scientific Officer
Andreas Jeromin
Co-Founder
Eric Reiman
Browse more venture capital transactions:
Prev: 7/18/2023: VitalConnect venture capital transaction
Next: 7/18/2023: Aviwell venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs